We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · December 29, 2016

Upfront Chemotherapy With Trastuzumab in Patients With HER2-Positive Breast Cancer

Annals of Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Annals of Oncology
Do All Patients With Advanced HER2 Positive Breast Cancer Need Upfront-Chemo When Receiving Trastuzumab? Randomized Phase III Trial SAKK 22/99
Ann. Oncol 2016 Dec 19;[EPub Ahead of Print], O Pagani, D Klingbiel, T Ruhstaller, F Nolè, S Eppenberger, C Oehlschlegel, J Bernhard, P Brauchli, D Hess, C Mamot, E Munzone, B Pestalozzi, M Rabaglio, S Aebi, K Ribi, C Rochlitz, K Rothgiesser, B Thürlimann, RV Moos, K Zaman, A Goldhirsch

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading